AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy

Degenerative vision loss significantly impacts a patient, but many find the treatment required to stabilize or improve vision — monthly injections into the eye — a huge turnoff. For that reason, a one-time gene therapy could change the course of the disease for many patients.

Regenxbio and pharma partner AbbVie are on their way to a potential solution with the retinal disease gene therapy candidate ABBV-RGX-314, designed to treat “wet” or neovascular age-related macular degeneration and diabetic retinopathy in one go.